These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20172343)

  • 21. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Münster.
    Stypmann J; Engelen MA; Eckernkemper S; Amler S; Gunia S; Sindermann JR; Rothenburger M; Rukosujew A; Drees G; Welp HA
    Transplant Proc; 2011 Jun; 43(5):1847-52. PubMed ID: 21693288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recovery of chronic renal impairment with sirolimus after lung transplantation.
    Venuta F; De Giacomo T; Rendina EA; Quattrucci S; Mercadante E; Cimino G; Ibrahim M; Diso D; Bachetoni A; Coloni GF
    Ann Thorac Surg; 2004 Dec; 78(6):1940-3. PubMed ID: 15561004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection.
    Sarahrudi K; Estenne M; Corris P; Niedermayer J; Knoop C; Glanville A; Chaparro C; Verleden G; Gerbase MW; Venuta F; Böttcher H; Aubert JD; Levvey B; Reichenspurner H; Auterith A; Klepetko W
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1126-32. PubMed ID: 15052212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
    J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
    Kovarik JM; Snell GI; Valentine V; Aris R; Chan CK; Schmidli H; Pirron U
    J Heart Lung Transplant; 2006 Apr; 25(4):440-6. PubMed ID: 16563975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.
    Kesten S; Chaparro C; Scavuzzo M; Gutierrez C
    J Heart Lung Transplant; 1997 Sep; 16(9):905-12. PubMed ID: 9322139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.
    Groetzner J; Wittwer T; Kaczmarek I; Ueberfuhr P; Strauch J; Nagib R; Meiser B; Franke U; Reichart B; Wahlers T
    Transplantation; 2006 Feb; 81(3):355-60. PubMed ID: 16477220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.
    Chiurchiu C; Carreño CA; Schiavelli R; Petrone H; Balaguer C; Trimarchi H; Pujol GS; Novoa P; Acosta F; González C; Arriola M; Massari PU;
    Transplant Proc; 2010; 42(1):277-9. PubMed ID: 20172329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function.
    Fernández A; Marcén R; Galeano C; Caldés S; Amezquita Y; Villafruela J; Pascual J; Burgos J; Rodríguez-Mendiola N; Ortuño J
    Transplant Proc; 2009; 41(6):2345-7. PubMed ID: 19715915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
    J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
    Hummel M
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S196-200; discussion S210-1. PubMed ID: 15774322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.